Welcome to our dedicated page for Lifestance Health Group SEC filings (Ticker: LFST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for LifeStance Health Group, Inc. (Nasdaq: LFST), a mental healthcare company focused on outpatient services. As a public company with common stock registered on The Nasdaq Stock Market LLC, LifeStance files documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.
LifeStance’s filings offer detailed information about its business as one of the nation’s largest providers of virtual and in-person outpatient mental healthcare. In these documents, the company describes its operations, risk factors, financial condition and results of operations. For example, current reports on Form 8-K have been used to furnish earnings press releases for specific quarters and to disclose changes in the board of directors, including director resignations and appointments with related equity awards under the company’s equity incentive plan.
Investors can review LifeStance’s discussion of non-GAAP financial measures such as Center Margin and Adjusted EBITDA, along with reconciliations to comparable GAAP measures, within its filings and related exhibits. The company also outlines forward-looking statements and associated risks, referring readers to the "Risk Factors" section of its Form 10-K and subsequent filings for more comprehensive risk disclosures.
On Stock Titan, LifeStance filings are updated as new documents are made available through the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy filings, highlight significant changes from prior periods and clarify technical language. Users can quickly identify items related to quarterly and annual results, governance events reported on Form 8-K and other regulatory disclosures relevant to LFST, while still having access to the full original documents for detailed review.
LifeStance Health Group director and officer Ryan Pardo reported a routine tax-related share withholding tied to vesting equity. On April 1, 2026, 9,376 shares of common stock were withheld at $6.37 per share to cover tax obligations from restricted stock units that vested on March 9, 2026. The filing states this was not an open-market sale. After the withholding, Pardo directly held 1,093,366 shares, and an additional 2,551,520 shares were reported as held indirectly by a trust, with beneficial ownership of those trust shares disclaimed except for his pecuniary interest.
LifeStance Health Group, Inc. officer Ryan McGroarty reported a Form 4 showing 24,255 shares of common stock withheld at $6.45 per share to cover tax obligations when restricted stock units vested on March 24, 2026. These withheld shares were not sold on the open market. After the transaction, McGroarty directly holds 772,235 shares of common stock.
LifeStance Health Group, Inc. reported that company officer Ryan McGroarty had restricted stock units vest on March 17, 2026, and 47,594 shares of common stock were withheld at $6.89 per share to cover tax obligations. The filing states this was not an open-market sale. After the withholding, McGroarty directly holds 796,490 shares of LifeStance common stock.
LifeStance Health Group director Kenneth A. Burdick reported compensation-related stock movements on March 9, 2026. He acquired common stock through vested restricted stock units and performance-based restricted stock units, with two grant or award acquisitions totaling 740,504 shares at a stated price of $0.00 per share.
To cover tax withholding obligations on these RSUs and PSUs, the issuer withheld 327,209 shares at $6.91 per share in three separate dispositions, which the footnotes clarify were not open-market sales. Following these transactions, Burdick directly held 3,425,315 shares, with an additional 46,511 shares held indirectly through Burdick Family LLC.
LifeStance Health Group, Inc. Chief Executive Officer David Bourdon reported stock-based compensation activity rather than open-market trading. On March 9, 2026, previously granted restricted stock units (RSUs) and performance-based restricted stock units (PSUs) vested, resulting in share awards recorded as acquisitions.
To cover tax withholding obligations tied to the vesting and net settlement of these RSUs and PSUs, the company withheld a total of 148,382 shares at a reported price of $6.91 per share across several transactions. The footnotes state these withholdings simply reduced the shares delivered to him and did not involve any open-market sales.
LifeStance Health Group, Inc. Chief Operating Officer Lisa K. Miller reported equity compensation activity involving restricted stock units and related tax withholding. On March 9, 2026, she acquired 26,836 shares of common stock at a stated price of $0.00 per share in a grant/award tied to vested performance-based restricted stock units previously granted on March 6, 2025.
On the same date, the issuer withheld 14,766 shares of common stock at $6.91 per share to satisfy tax obligations for vested RSUs and separately withheld 13,446 shares at $6.91 per share for tax obligations related to vested PSUs. Footnotes specify these withheld shares reduce the shares issued to Miller and do not constitute any open-market sale. After these transactions, she directly owned 329,201 shares of common stock.
LifeStance Health Group Chief People Officer Ann Varanakis reported compensation-related share activity in connection with vested restricted stock units (RSUs) and performance-based RSUs (PSUs) on March 9, 2026.
She acquired 26,836 and 59,789 shares of common stock at $0.00 per share through RSU and PSU settlements. To cover tax withholding obligations on these vestings, the issuer withheld a total of 44,963 shares at a reference price of $6.91 per share. The footnotes state these withholdings reduce shares delivered and do not involve any open-market sales. Following these transactions, Varanakis directly holds 422,037 shares of LifeStance common stock.
LifeStance Health Group director and officer Ryan Pardo reported equity compensation vesting and related tax withholding transactions in Common Stock. On March 9, 2026, he received stock awards of 40,254 and 105,711 shares at no cost as restricted and performance-based units vested.
To cover tax obligations on these vestings, the issuer withheld 12,280, 15,841, and 38,479 shares at $6.91 per share, which the footnotes state are not open-market sales. Following these transactions, Pardo directly owned 1,102,742 shares and had indirect exposure to 2,551,520 shares held by the Kimberly Pardo Irrevocable Trust, where he disclaims beneficial ownership beyond any pecuniary interest.
LifeStance Health Group, Inc. executive Ryan McGroarty reported equity compensation activity involving performance-based restricted stock units (PSUs) that vested on March 9, 2026. He acquired 127,878 shares of common stock from PSUs granted on March 17, 2025, and 65,168 shares from PSUs granted on March 24, 2025.
To cover tax withholding obligations on these PSU settlements, the issuer withheld 50,929 shares and 25,644 shares at a price of $6.91 per share. The footnotes state these withholdings reduced the shares delivered on vesting and did not involve any open-market sales.
After these transactions, McGroarty directly held 844,084 shares of LifeStance common stock.
LifeStance Health Group, Inc. Chief Technology Officer Vukasin Paunovich reported equity compensation activity tied to performance-based restricted stock units. On March 9, 2026, he acquired 62,935 shares of common stock at $0.00 per share upon vesting of previously granted PSUs. On the same date, 18,541 shares were withheld at $6.91 per share to satisfy tax withholding obligations, which the company notes did not involve any open-market sale. Following these transactions, Paunovich directly holds 309,296 shares of common stock.